(10-bromodecyl)phosphonic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: (10-bromodecyl)phosphonic acid
• 英文别名: 10-Bromodecylphosphonic acid；10-bromodecylphosphonic acid
• 化学式: C₁₀H₂₂BrO₃P
• 分子量: 301.161
• InChiKey: PZKCVYRQOBKBBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (10-bromodecyl)phosphonic acid 在 N,N'-二环己基碳二亚胺 作用下， 以 吡啶 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.17h， 生成 (6S,8S,9R,10S,11S,13S,14S,16R,17R)-17-(((10-(((4-(2-((2S)-2-(2-(cyclooct-2-yn-1-yloxy)acetamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl)oxy)(hydroxy)phosphoryl)decyl)thio)carbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate
  参考文献：
  名称：

  [EN] PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS
  [FR] LIEURS DE PHOSPHONATE ET LEUR UTILISATION POUR FACILITER LA RÉTENTION CELLULAIRE DE COMPOSÉS

  摘要：

  公开号：

  WO2017132103A3

文献信息

• Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
  作者：Philip E. Brandish、Anthony Palmieri、Svetlana Antonenko、Maribel Beaumont、Lia Benso、Mark Cancilla、Mangeng Cheng、Laurence Fayadat-Dilman、Guo Feng、Isabel Figueroa、Juhi Firdos、Robert Garbaccio、Laura Garvin-Queen、Dennis Gately、Prasanthi Geda、Christopher Haines、SuChun Hseih、Douglas Hodges、Jeffrey Kern、Nickolas Knudsen、Kristen Kwasnjuk、Linda Liang、Huiping Ma、Anthony Manibusan、Paul L. Miller、Lily Y. Moy、Yujie Qu、Sanjiv Shah、John S. Shin、Peter Stivers、Ying Sun、Daniela Tomazela、Hyun Chong Woo、Dennis Zaller、Shuli Zhang、Yiwei Zhang、Mark Zielstorff

  DOI：10.1021/acs.bioconjchem.8b00312

  日期：2018.7.18

  Glucocorticoids (GCs) are excellent anti-inflammatory drugs but are dose-limited by on-target toxicity. We sought to solve this problem by delivering GCs to immune cells with antibody–drug conjugates (ADCs) using antibodies containing site-specific incorporation of a non-natural amino acid, novel linker chemistry for in vitro and in vivo stability, and existing and novel glucocorticoid receptor (GR)

  糖皮质激素（GCs）是出色的抗炎药，但受靶标毒性限制剂量。我们试图通过使用包含非天然氨基酸的位点特异性掺入的抗体，用于体外和体内稳定性的新型接头化学以及现有的和新型的抗体，通过抗体-药物偶联物（ADC）将GC递送至免疫细胞来解决此问题糖皮质激素受体（GR）激动剂作为有效载荷。我们将丙酸氟替卡松导向人抗原呈递免疫细胞，以提供依赖于靶向抗原的GR激活。然而，作用机理研究指出，游离有效载荷在组织培养上清液中的积累是活性的主要驱动力，实际上向人CD74转基因小鼠施用ADC未能激活脾脏B细胞中的GR靶基因。考虑到释放的有效载荷的耗散，我们设计了一种ADC，该ADC带有一种新型GR激动剂有效载荷，具有降低的渗透性，可在人B细胞中提供细胞内在活性。我们的工作表明，靶向抗体为在肿瘤学领域之外拯救现有和新的剂量受限药物提供了巨大的潜力。
• Phosphonate linkers and their use to facilitate cellular retention of compounds
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10869929B2

  公开（公告）日：2020-12-22

  Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.

  本文介绍了膦酸盐连接体及其在将具有被动细胞渗透性的化合物输送到细胞中的用途，其中膦酸盐基团可促进化合物在细胞中的保留。
• DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS
  申请人：Agrawal C. Mauli

  公开号：US20090123516A1

  公开（公告）日：2009-05-14

  Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.
• PHOSPONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS
  申请人：Garbaccio Robert M.

  公开号：US20190030171A1

  公开（公告）日：2019-01-31

  Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
• PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210015930A1

  公开（公告）日：2021-01-21

  Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.